Latest Conference Articles

Pirtobrutinib demonstrates an impressive 81.6% response rate in CLL/SLL patients previously treated with BTK inhibitors, showcasing its efficacy and safety.

Zanubrutinib shows sustained efficacy and safety in relapsed/refractory CLL, with a median progression-free survival of 52.5 months in long-term follow-up.

Pirtobrutinib shows superior overall response rates and promising progression-free survival compared to ibrutinib in treating chronic lymphocytic leukemia.

Epcoritamab combined with rituximab and lenalidomide shows remarkable efficacy in treating relapsed follicular lymphoma, setting a new standard of care.

Azacitidine plus venetoclax significantly enhances event-free survival and quality of life in acute myeloid leukemia patients compared with traditional chemotherapy.

Gintemetostat shows promising efficacy and safety in heavily pretreated multiple myeloma patients, paving the way for future combination therapies.

Epcoritamab combined with R-mini-CHOP shows promising efficacy and safety in elderly DLBCL patients, achieving high response rates and durable remissions.

Rusfertide shows sustained hematocrit control and high phlebotomy ineligibility in polycythemia vera patients, demonstrating safety and efficacy through 52 weeks.

New findings reveal the feasibility and safety of transitioning axatilimab dosing for chronic graft-vs-host disease, showing promising response rates.

New research reveals KRd therapy significantly enhances progression-free survival in newly diagnosed multiple myeloma compared to traditional VRd treatment.

Odronextamab shows promising efficacy in treating untreated DLBCL, achieving high response rates when combined with CHOP chemotherapy in early trials.

Cilta-cel therapy shows improved outcomes in earlier treatment lines for relapsed/refractory multiple myeloma, enhancing immune fitness and survival rates.

Lisaftoclax shows promising efficacy and safety in treating relapsed/refractory CLL/SLL, achieving a 62.5% response rate and 23.89 months progression-free survival.

Discover the most anticipated breast cancer research at SABCS 2025, featuring groundbreaking abstracts in HR+, HER2+, and TNBC. Vote now!

Discover the most anticipated abstracts in hematologic malignancies at the 2025 ASH Meeting, featuring groundbreaking studies and innovative therapies.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.

Vorasidenib significantly reduces tumor growth rates in grade 2 glioma patients, improving progression-free survival and time to next intervention.

A phase 1 study reveals that sequential CR7-GD2 CAR T-cell therapy administration is better tolerated in pediatric CNS tumor patients than concurrent methods.

Discover the most anticipated abstracts at the 67th ASH Annual Meeting and Exposition, showcasing groundbreaking research in hematologic malignancies and innovative treatments.

New research from ESMO 2025 reveals significant survival benefits of intensified androgen blockade over traditional therapies for advanced prostate cancer.

New findings reveal that GDF-15 neutralization with visugromab and nivolumab significantly enhances long-term responses in advanced cancer patients.

Explore the evolving role of medical oncologists in treating non–muscle invasive bladder cancer with innovative immunotherapy options and trial insights.

High LAG3 expression in metastatic renal cell carcinoma enhances initial immunotherapy response but does not improve long-term survival outcomes.

Bispecific and trispecific antibodies show efficacy in multiple myeloma, moving into earlier lines of therapy.

Small cell lung cancer treatment evolves with groundbreaking therapies, improving survival rates and offering new hope for patients in 2024 and beyond.

A phase 1b/2 trial shows triplet therapy for advanced renal cell carcinoma is feasible but lacks significant response improvement over standard treatment.